Creo Medical (UK) Performance
| CREO Stock | 14.25 0.25 1.72% |
The firm shows a Beta (market volatility) of -0.42, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Creo Medical are expected to decrease at a much lower rate. During the bear market, Creo Medical is likely to outperform the market. At this point, Creo Medical Group has a negative expected return of -1.03%. Please make sure to confirm Creo Medical's standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if Creo Medical Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Creo Medical Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | Creo Medical Group PLC Screens Well But There Might Be A Catch - Simply Wall St | 09/18/2024 |
2 | Creo Medical Group First Half 2024 Earnings UK0.034 loss per share - Simply Wall St | 10/02/2024 |
3 | Creo Medical Directors Boost Shareholdings Amid Fundraising - TipRanks | 10/21/2024 |
| Begin Period Cash Flow | 13.1 M |
Creo |
Creo Medical Relative Risk vs. Return Landscape
If you would invest 2,875 in Creo Medical Group on September 12, 2024 and sell it today you would lose (1,450) from holding Creo Medical Group or give up 50.43% of portfolio value over 90 days. Creo Medical Group is generating negative expected returns and assumes 3.4451% volatility on return distribution over the 90 days horizon. Simply put, 30% of stocks are less volatile than Creo, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Creo Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Creo Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Creo Medical Group, and traders can use it to determine the average amount a Creo Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2996
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CREO |
Estimated Market Risk
| 3.45 actual daily | 30 70% of assets are more volatile |
Expected Return
| -1.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.3 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Creo Medical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Creo Medical by adding Creo Medical to a well-diversified portfolio.
Creo Medical Fundamentals Growth
Creo Stock prices reflect investors' perceptions of the future prospects and financial health of Creo Medical, and Creo Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Creo Stock performance.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.74) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 64.16 M | ||||
| Shares Outstanding | 412.15 M | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 1.97 X | ||||
| Revenue | 30.8 M | ||||
| Gross Profit | 11.59 M | ||||
| EBITDA | (20.7 M) | ||||
| Net Income | (21.7 M) | ||||
| Total Debt | 8.3 M | ||||
| Book Value Per Share | 0.13 X | ||||
| Cash Flow From Operations | (21.6 M) | ||||
| Earnings Per Share | (0.06) X | ||||
| Total Asset | 76.6 M | ||||
| Retained Earnings | (144.4 M) | ||||
About Creo Medical Performance
Assessing Creo Medical's fundamental ratios provides investors with valuable insights into Creo Medical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Creo Medical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Creo Medical is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Creo Medical Group performance evaluation
Checking the ongoing alerts about Creo Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Creo Medical Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Creo Medical Group generated a negative expected return over the last 90 days | |
| Creo Medical Group has high historical volatility and very poor performance | |
| Creo Medical Group has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 30.8 M. Net Loss for the year was (21.7 M) with profit before overhead, payroll, taxes, and interest of 11.59 M. | |
| Creo Medical generates negative cash flow from operations | |
| About 20.0% of the company shares are held by company insiders |
- Analyzing Creo Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Creo Medical's stock is overvalued or undervalued compared to its peers.
- Examining Creo Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Creo Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Creo Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Creo Medical's stock. These opinions can provide insight into Creo Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Creo Stock Analysis
When running Creo Medical's price analysis, check to measure Creo Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Creo Medical is operating at the current time. Most of Creo Medical's value examination focuses on studying past and present price action to predict the probability of Creo Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Creo Medical's price. Additionally, you may evaluate how the addition of Creo Medical to your portfolios can decrease your overall portfolio volatility.